Boston Scientific Corporation
Financials
Valuation Metrics
Boston Scientific Corporation's Market Cap is $72.00B. At end of 2025 it was $141.38B. Ranked #241 of 3,112 in US market (top 8%), #171 of 1,667 on NYSE (top 10%), #13 of 206 in Health Care Equipment & Services (top 6%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $72.00B | US#241/3,112 Sec#13/206 |
| Revenue | $20.61B | US#318/3,112 Sec#22/206 |
| Net Income | $3.55B | US#199/3,112 Sec#10/206 |
| Total Assets | $44.35B | US#360/3,112 Sec#17/206 |
| Net Assets | $25.86B | US#190/3,112 Sec#9/206 |
| Employees | 59,000 | US#150/3,112 Sec#17/206 |
| Value | ||
| P/E | 20.26x | US#1,045/3,112 Sec#24/206 |
| P/B | 2.78x | US#1,590/3,112 Sec#91/206 |
| PEG | 0.21x | US#316/3,112 Sec#8/206 |
| P/S | 3.49x | US#1,939/3,112 Sec#134/206 |
| EV/EBITDA | 14.40x | US#1,406/3,112 Sec#54/206 |
| FCF Yield | 4.78% | US#1,330/3,112 Sec#68/206 |
| Profitability | ||
| ROE | 13.74% | US#961/3,112 Sec#47/206 |
| ROA | 8.01% | US#617/3,112 Sec#38/206 |
| Op. Margin | 20.12% | US#903/3,112 Sec#31/206 |
| Revenue Growth | 11.58% | US#1,168/3,112 Sec#80/206 |
| Earnings Growth | 98.37% | US#351/3,112 Sec#15/206 |
| Financial Health | ||
| Debt Ratio | 70.55% | US#789/3,112 Sec#85/206 |
| Total Debt | $11.03B | US#370/3,112 Sec#20/206 |
| FCF | $3.44B | US#214/3,112 Sec#14/206 |
| Cash | $1.52B | US#521/3,112 Sec#31/206 |
| Current Ratio | 1.90x | US#1,314/3,112 Sec#115/206 |
| Net Debt/EBITDA | 1.68x | US#1,263/3,112 Sec#72/206 |
| Performance | ||
| 1Y Return | -54.05% | US#3,004/3,112 Sec#196/206 |
| 1M Return | 7.31% | US#733/3,112 Sec#58/206 |
| From 52W High | -55.76% | US#2,874/3,112 Sec#190/206 |
| 1Y MDD | -60.58% | US#2,736/3,112 Sec#176/206 |
| Trading | ||
| Volume | 16,536,243 shares | US#95/3,112 Sec#1/206 |
| Trading Value | $799M | US#124/3,112 Sec#5/206 |
| Per Share | ||
| EPS | $1.95 | US#1,287/3,112 Sec#69/206 |
| BPS | $16.34 | US#1,405/3,112 Sec#80/206 |
Company Info
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.